antivir
therapi
one
excit
aspect
virolog
sinc
success
employ
basic
scienc
gener
effect
treatment
seriou
viral
infect
tabl
list
select
exampl
human
viral
diseas
establish
antivir
drug
therapi
human
immunodefici
viru
hiv
infect
demonstr
potenti
impact
antivir
lethal
chronic
infect
lifesav
therapi
administ
million
individu
dramat
advanc
recapitul
treatment
hepat
c
viru
hcv
infect
develop
new
antivir
drug
much
work
progress
activ
drug
discoveri
program
filovirus
coronavirus
dengu
other
conceptu
approach
drug
develop
flux
past
primari
focu
upon
viru
target
continu
product
strategi
complement
wider
set
approach
present
strategi
includ
compound
target
gener
viral
target
rna
dna
synthesi
could
activ
rang
differ
virus
compound
direct
host
cellular
activ
necessari
viru
replic
might
target
one
spectrum
virus
figur
furthermor
establish
methodolog
drug
discoveri
supplement
use
larg
databas
evolv
method
comput
biolog
final
increas
emphasi
repurpos
drug
alreadi
approv
human
use
driven
inordin
time
cost
drug
develop
chapter
explor
issu
begin
discuss
mechan
antivir
agent
act
illustr
select
exampl
present
attempt
highlight
import
viral
pathogenesi
design
differ
therapeut
strategi
individu
viral
diseas
continu
brief
discuss
pharmacodynam
toxic
critic
hurdl
safe
effect
drug
must
pass
section
close
discuss
new
horizon
drug
develop
pathway
drug
develop
challeng
next
describ
follow
overview
viru
infect
effect
therapi
avail
conclud
section
futur
antivir
therapi
viral
protein
current
understand
molecular
replic
individu
virus
provid
detail
elucid
role
individu
viral
protein
possibl
map
function
domain
within
viral
protein
imag
structur
data
use
ration
drug
design
either
synthes
small
molecul
bind
activ
site
viral
protein
develop
highthroughput
screen
procedur
test
larg
batteri
small
molecul
block
specif
activ
hiv
serv
use
exampl
sinc
exhaust
effort
develop
antivir
drug
exploit
mani
viral
protein
antihiv
drug
target
one
viral
enzym
either
revers
transcriptas
proteas
integras
tabl
particular
mani
drug
block
revers
transcript
enzymat
activ
express
normal
cell
two
class
revers
transcriptas
inhibitor
nucleosid
nonnucleosid
nrti
nnrti
respect
nrti
compound
incorpor
nascent
dna
chain
block
elong
nnrti
bind
directli
enzym
inhibit
function
may
lead
degrad
major
enzymat
drug
target
viral
proteas
cut
gag
pol
viral
polypeptid
produc
matur
protein
proteas
inhibitor
usual
bind
catalyt
site
proteas
molecul
addit
drug
inhibit
step
hiv
replic
cycl
initi
step
hiv
cellular
entri
bind
viral
cellular
coreceptor
see
chapter
hivaid
hiv
undergo
conform
chang
expos
ntermin
fusion
domain
insert
plasma
membran
host
cell
close
n
terminu
heptad
repeat
form
threehelix
bundl
associ
anoth
threehelix
bundl
c
terminu
forc
molecul
hairpin
variou
scientif
strategi
develop
antivir
drug
left
panel
directact
antivir
target
specif
viral
protein
aim
singl
viru
target
target
multipl
virus
cartoon
show
inhibitor
viral
polymeras
proteas
viral
protein
may
also
target
right
panel
drug
target
cellular
process
essenti
replic
one
sever
virus
cartoon
show
sever
class
inhibitor
mani
cellular
function
could
target
reconceiv
bekerman
einav
cypa
cyclophilin
lazzarin
et
al
viral
mutagen
surviv
virus
depend
part
abil
evolv
respons
antivir
pressur
host
immun
respons
perspect
rapid
mutat
rate
rna
virus
particular
facilit
select
fit
mutant
among
everpres
swarm
genet
variant
theori
polymeras
rna
virus
evolv
optim
balanc
process
fidel
mutat
rate
permit
gener
larg
number
progeni
mani
genet
variant
variant
facilit
rapid
adapt
select
pressur
immun
respons
drug
treatment
counterintuit
approach
antivir
drug
use
mutagen
increas
viral
mutat
rate
fit
variant
overwhelm
less
fit
nonsens
mutant
lead
lethal
accumul
error
error
catastroph
discuss
chapter
viru
evolut
least
one
antivir
drug
ribavirin
nucleosid
analogu
propos
act
mechan
shown
increas
mutat
rate
decreas
product
infecti
particl
sever
virus
includ
polioviru
hantaan
viru
rna
interfer
rnai
rna
interfer
discov
serendipit
attempt
overexpress
specif
plant
gene
use
viral
vector
instead
result
knockout
silenc
gene
rnai
describ
detail
chapter
concept
viral
pathogenesi
potenti
antivir
therapeut
shown
proofofconcept
clinic
trial
hepat
c
figur
cellular
target
theoret
advantag
viral
target
sinc
undergo
escap
mutat
hand
target
cellular
molecul
interfer
vital
host
function
could
problem
longterm
treatment
might
critic
impedi
acut
infect
cellular
target
major
focu
past
receiv
increas
attent
tabl
techniqu
identifi
potenti
cellular
target
cover
chapter
system
virolog
chapter
virushost
interactom
chemokin
receptor
coreceptor
hiv
see
chapter
hivaid
individu
homozyg
mutat
delta
mutat
prevent
express
host
gene
person
show
ill
effect
mutat
resist
hiv
infect
observ
suggest
small
molecul
block
receptor
domain
might
safe
use
treat
hiv
infect
without
interf
essenti
cellular
function
fatkenheu
et
al
maraviroc
inhibitor
proven
effect
hiv
treatment
cyclosporin
csa
approv
drug
bind
toand
inactivatesa
cellular
molecul
cyclophilin
cyclophilin
famili
cistran
isomeras
convert
prolin
tran
ci
form
famili
cyclophilin
play
essenti
role
mani
cellular
process
requir
protein
fold
traffick
activ
essenti
replic
hcv
interestingli
csa
approv
immunosuppress
drug
discov
serendipit
strong
activ
hcv
lin
gallay
note
mice
cyclophilin
knockout
gener
healthi
molecul
seem
essenti
life
least
shoebox
anoth
focu
cellular
target
attempt
develop
panviru
strategi
antivir
therapeut
one
exampl
direct
phosphatidylserin
anion
phospholipid
locat
inner
leaflet
plasma
membran
expos
virusinfect
cell
antibodi
direct
anion
phospholipid
figur
microrna
mirna
treatment
potenti
treatment
modal
select
human
viral
infect
exampl
trial
target
treatment
hcv
mirna
express
liver
cell
replic
hcv
depend
upon
function
interact
genom
shown
mean
chang
hcv
rna
level
baselin
patient
receiv
mg
miravirsen
antisens
oligonucleotid
sequest
per
kilogram
bodi
weight
compar
placebo
miravirsen
administ
weekli
subcutan
inject
first
day
studi
shade
dash
line
indic
chang
baselin
redrawn
data
janssen
et
al
interf
replic
arenavirus
soar
et
al
antibodi
treatment
infect
guinea
pig
spare
potenti
lethal
infect
pichind
arenaviru
pathogenesi
transmiss
epidemiolog
characterist
individu
virus
import
determin
potenti
efficaci
antivir
drug
virus
short
incub
period
gener
time
spread
rapidli
tend
poor
candid
antivir
treatment
difficult
complet
diagnosi
initi
therapi
time
fashion
influenza
good
exampl
seriou
ill
short
incub
period
h
neuraminidas
inhibitor
quit
effect
antiinfluenza
drug
need
given
prior
infect
soon
symptom
appear
drawback
may
overcom
certain
circumst
presenc
pandem
wave
influenza
spread
across
commun
antivir
drug
could
wide
administ
shortterm
prophylact
therebi
anticip
potenti
infect
persist
viral
infect
caus
signific
chronic
ill
attract
target
antivir
treatment
slow
cours
permit
accur
diagnosi
evalu
prior
initi
therapi
furthermor
persist
infect
hepat
b
hepat
c
carri
longterm
risk
liver
failur
hepatocellular
cancer
estim
million
case
hepat
c
million
case
hepat
b
global
diseas
constitut
signific
opportun
treatment
effect
therapeut
intervent
particularli
longlast
viral
suppress
even
viral
clearanc
cure
would
significantli
reduc
diseas
burden
mani
persist
infect
dynam
balanc
persist
viru
host
defens
thu
person
infect
hepat
b
viru
hbv
abl
clear
infect
even
year
persist
pattern
two
implic
first
suggest
antivir
therapi
might
tip
balanc
favor
host
lead
viral
clearanc
second
suggest
antivir
antibodi
might
use
synergi
antivir
drug
improv
therapeut
outcom
therapeut
antibodi
neutral
antibodi
major
mediat
preexposur
protect
confer
mani
establish
viral
vaccin
see
chapter
viral
vaccin
addit
antibodi
induc
primari
infect
play
role
clearanc
recoveri
certain
acut
viral
diseas
therefor
plausibl
passiv
antibodi
administ
acut
viral
infect
might
therapeut
primari
infect
west
nile
viru
wnv
flaviviru
one
exampl
follow
transmiss
mosquito
bite
wnv
initi
plasma
viremia
follow
invas
central
nervou
system
result
potenti
fatal
enceph
experi
immunolog
defici
mice
shown
antibodi
cellular
immun
play
role
outcom
infect
surprisingli
antibodi
also
play
role
clearanc
viru
central
nervou
system
even
infect
well
establish
neuron
administ
mice
undergo
acut
wnv
enceph
passiv
antibodi
markedli
improv
surviv
least
experiment
condit
recent
found
neutral
antibodi
effect
use
treatment
acut
infect
ebola
viru
anim
model
see
garcia
et
al
innat
immun
respons
discuss
chapter
innat
immun
ifn
induc
complex
pleiotrop
respons
inhibit
viral
replic
sever
differ
way
addit
activ
antigenspecif
adapt
immun
respons
use
exogen
ifn
antivir
therapi
tri
mani
viral
infect
butto
dateha
use
mainli
treatment
two
persist
infect
hcv
hbv
discuss
howev
ifn
therapi
substanti
unwant
side
effect
human
limit
practic
util
cytokin
storm
sever
seriou
viral
infect
human
produc
diseas
via
excess
imbalanc
host
respons
lead
intens
dysregul
proinflammatori
cytokin
chemokin
cytokin
storm
caus
rang
seriou
diseas
manifest
includ
acut
lung
injuri
associ
respiratori
virus
highli
pathogen
influenza
virus
avian
sar
shock
syndrom
fatal
case
ebola
viru
infect
recent
studi
hostviru
interactom
see
chapter
virushost
interactom
made
possibl
identifi
compon
patholog
host
respons
insight
may
use
formul
new
therapi
amelior
excess
deleteri
innat
respons
drugresist
viral
mutant
constitut
major
problem
antivir
therapi
frequenc
resist
mutant
vari
wide
see
chapter
viru
evolut
determin
number
factor
sidebar
rna
virus
mutat
rate
estim
mutat
base
replic
much
higher
rate
dna
virus
differ
reflect
poor
fidel
well
absenc
cellular
proofread
mechan
rna
polymeras
replic
rate
viru
specif
infect
vari
wide
influenc
rate
mutant
virion
produc
instanc
estim
infect
virion
produc
daili
would
yield
virion
singl
point
mutat
averag
mutant
base
day
end
scale
human
papillomaviru
hpv
dna
viru
replic
slowli
vivo
mutant
virion
would
synthes
daili
differ
reflect
observ
individu
primari
hiv
isol
consist
swarm
virus
sequenc
whichaft
sever
year
infectionvari
differ
gene
contrast
primari
isol
dna
virus
show
much
less
variat
differ
class
drug
target
divers
viral
function
vari
import
viral
replic
individu
drug
vari
degre
block
target
function
furthermor
resist
mutant
vari
abil
replic
presenc
drug
alsoabs
drugin
replic
capac
fit
nuanc
reflect
observ
differ
nrtiswhich
direct
viral
functionselect
differ
escap
mutat
vivo
select
pressur
specif
drug
depend
upon
intrins
abil
block
essenti
viru
function
pharmacodynam
determin
actual
concentr
site
viral
replic
select
pressur
increas
rel
advantag
mutant
increas
rate
replic
wildtyp
viru
decreas
replic
diminish
probabl
resist
virus
emerg
diminish
select
escap
mutant
maxim
drug
concentr
high
enough
select
resist
mutant
high
substanti
inhibit
viru
replic
see
chapter
viral
evolut
one
import
implic
forego
consider
potenti
advantag
multidrug
therapi
viru
replic
presenc
three
divers
drug
select
differ
resist
mutat
frequenc
tripl
mutant
assum
interact
variou
mutat
would
occur
might
rare
phenomenon
case
comparison
multipl
drug
therapi
new
compound
introduc
tang
shafer
dramat
stepwis
increas
efficaci
addit
drug
figur
tripl
drug
therapi
sidebar
determin
antivir
drug
resist
l
variat
viral
mutat
rate
greater
rna
dna
virus
l
variat
vivo
viral
replic
determin
rate
mutant
gener
l
variat
structur
mechan
drugmedi
viral
inactiv
determin
frequenc
fit
resist
mutant
l
variat
drugmedi
select
pressur
vivo
determin
rel
replic
rate
wildtyp
mutant
virus
l
concurr
use
sever
drug
act
upon
differ
viral
function
markedli
reduc
frequenc
resist
virion
sinc
must
possess
multipl
mutat
usual
requir
suppress
viral
replic
minim
escap
mutat
critic
aspect
drug
efficaci
behavior
vivo
mani
compound
appear
activ
cell
cultur
system
fail
test
anim
pharmacodynam
drug
depend
least
follow
paramet
compound
solubl
absorb
given
mouth
requir
inject
even
intraven
administr
drug
activ
administ
formul
requir
biochem
process
liver
activ
fast
compound
releas
blood
circul
free
molecul
plasma
bind
albumin
plasma
protein
drug
act
blood
specif
target
tissu
fast
enter
target
tissu
halflif
compound
blood
tissu
drug
inactiv
liver
excret
urin
intestin
tract
drug
achiev
therapeut
level
blood
target
tissu
dosag
regimen
requir
maintain
therapeut
level
thu
complex
set
experi
must
conduct
determin
whether
candid
compound
meet
pharmacodynam
criteria
make
practic
use
relat
pharmacodynam
often
studi
concert
toxic
usual
standard
batteri
test
conduct
detect
unwant
side
effect
candid
drug
toxic
effect
may
unpredict
mode
action
antivir
compound
pharmacodynam
toxic
studi
requir
food
drug
administr
part
applic
ind
investig
new
drug
must
obtain
prior
phase
trial
human
see
new
era
drug
develop
dawn
base
advanc
comput
biolog
larg
public
databas
also
broaden
conceptu
view
includ
hostpathogen
interactom
cellular
target
drug
repurpos
casadeval
pirofski
major
incent
ineffici
establish
develop
pathway
mani
year
requir
inordin
cost
low
yield
discuss
tabl
list
recent
public
divers
applic
comput
biolog
propos
drug
discoveri
sever
exampl
illustr
approach
taken
one
comput
approach
use
josset
et
al
studi
transcriptom
respons
virul
influenza
virus
season
virus
human
lung
epitheli
cell
system
identifi
potenti
antivir
compound
databas
approach
use
reli
assumpt
effect
drug
would
invers
effect
cellular
transcript
respons
target
viru
use
public
avail
databas
connect
map
contain
thousand
gene
express
profil
thousand
compound
sever
drug
identifi
potenti
antivir
viru
includ
cellular
kinas
inhibitor
well
fdaapprov
drug
troglitazon
minocyclin
similar
approach
taken
number
virus
viru
mutant
may
escap
singl
even
two
drug
much
less
like
escap
three
drug
administ
simultan
hivinfect
patient
start
regimen
two
nucleosid
azidothymidin
zdv
lamivudin
proteas
inhibitor
indinavir
idv
combin
three
drug
decreas
level
blood
hiv
rna
baselin
shown
rise
plasma
hiv
rna
sever
month
nucleosid
proteas
arm
associ
emerg
resist
mutat
gene
respect
target
enzym
drawn
data
gulick
et
al
dengu
hepat
c
munk
et
al
brass
et
al
cando
comput
analysi
novel
drug
opportun
platform
focus
potenti
interact
small
molecul
protein
interest
mini
et
al
input
come
varieti
sourc
includ
structur
homolog
curat
databas
inform
scientif
literatur
goal
identifi
small
molecul
might
interact
specif
protein
therebi
interfer
function
could
appli
block
viral
function
host
protein
critic
viral
replic
set
cell
line
use
verbist
et
al
test
effect
drug
candid
gene
transcript
use
microarray
readout
focu
predetermin
set
gene
whichif
upregulatedcould
toxic
othersif
upregulatedcould
therapeut
data
use
make
gonogo
decis
aid
select
compound
investig
broadspectrum
antivir
drug
virus
share
step
replic
strategi
would
possibl
design
directact
antivir
compound
would
inhibit
famili
virus
contrast
singl
target
sever
compound
inhibit
rna
polymeras
investig
potenti
treat
number
virus
warren
et
al
furuta
et
al
brincidofovir
nucleotid
analogu
block
action
dna
polymeras
propos
candid
treatment
sever
dsdna
virus
florescu
et
al
antivir
cellular
target
note
exampl
cellular
target
thatif
compromisedwil
inhibit
individu
class
virus
tabl
system
approach
exploit
potenti
opportun
drug
discoveri
first
offer
systemat
approach
identifi
cellular
enzym
protein
process
essenti
replic
viru
second
provid
broadbas
approachus
sirna
knockout
methodsto
determin
potenti
cellular
target
may
expend
third
enabl
search
potenti
inhibitor
cellular
target
fourth
use
screen
select
anticellular
compound
abil
inhibit
viru
replic
vitro
vivo
although
method
yet
produc
approv
therapeut
variou
exampl
cite
tabl
demonstr
potenti
newer
approach
drug
discoveri
new
drug
develop
begin
short
discuss
process
drug
discoveri
give
sens
scope
divers
approv
drug
variabl
influenc
efficaci
section
present
exampl
approv
antivir
therapi
detail
inform
avail
clinic
text
review
see
read
new
antivir
drug
follow
wellworn
development
pathway
usual
requir
drug
approv
use
human
subject
overal
slow
cumbersom
expens
process
take
least
year
cost
billion
figur
show
typic
pathway
drug
develop
unit
state
figur
show
cost
candid
compound
never
make
market
fail
pass
one
success
hurdl
shown
figur
guesstim
compound
make
begin
end
process
drug
develop
process
divid
three
phase
basic
research
preclin
studi
clinic
trial
basic
research
involv
identif
druggabl
target
molecul
step
viral
replic
preclin
studi
requir
inform
highthroughput
search
compound
inactiv
target
molecul
evid
work
anim
model
viral
diseas
studi
anim
model
complex
set
pharmacolog
paramet
must
meet
practic
standard
includ
dose
rout
administr
pharmacodynam
frequenc
administr
concentr
blood
key
target
organ
possibl
requir
activ
liver
care
must
taken
search
possibl
toxic
effect
therapeut
drug
level
past
step
compound
becom
elig
test
human
assum
ind
approv
obtain
usa
food
drug
administr
typic
three
sequenti
phase
clinic
trial
phase
focus
safeti
phase
ii
paramet
serv
surrog
efficaci
phase
iiicontrol
trial
human
popul
determin
efficaci
safeti
sever
consequ
slow
expens
process
countri
earli
basic
research
identifi
potenti
druggabl
target
take
place
notforprofit
research
institut
fund
govern
privat
organ
drug
develop
usual
conduct
forprofit
pharmaceut
biotechnolog
compani
consid
cost
understand
reluct
develop
drug
unless
remun
potenti
market
aid
hepat
c
good
exampl
diseas
attract
market
ebola
exampl
orphan
diseas
cumul
cost
million
dollar
limit
potenti
marketat
least
pandem
drug
repurpos
impedi
new
drug
develop
activ
field
drug
repurpos
larg
number
drug
direct
cellular
pathway
approv
us
food
drug
administr
human
use
possibl
could
also
antivir
activ
either
block
cellular
pathway
critic
viru
replic
amelior
innat
respons
viru
whichin
instancescontribut
diseas
pathogenesi
ekin
et
al
previous
approv
drug
identifi
effect
antivir
shortcut
drug
develop
pathway
could
quicker
less
expens
dyall
et
al
number
strategi
drug
repurpos
note
tabl
one
exampl
cyclosporin
describ
compound
inhibit
matur
hcv
nonimmunosuppress
deriv
cyclosporin
maintain
activ
hcv
includ
trial
patient
hcvinduc
inflammatori
liver
diseas
induc
antivir
respons
due
anticyclophilin
activ
influenza
one
preval
viral
diseas
affect
estim
popul
annual
million
case
sever
respiratori
ill
million
death
unit
state
alon
annual
excess
mortal
attribut
influenza
explain
pathogenesi
influenzait
short
incub
period
h
acut
coursemak
difficult
target
antivir
therapi
inhibitor
viral
entri
inhibitor
one
step
cellular
entri
pathway
influenza
viru
endocytos
acid
vacuol
h
ion
channel
form
viral
protein
facilit
acidif
interior
virion
turn
permit
dissoci
matrix
protein
ribonucleoprotein
viral
core
enter
cytosol
initi
replic
amantadin
rimantadin
relat
drug
bind
ion
channel
influenza
virus
prevent
final
step
viral
entri
drug
proven
effect
prophylaxi
therapi
howev
drugresist
mutant
frequent
isol
patient
day
therapi
moreov
circul
influenza
virus
past
decad
maintain
resist
class
drug
inhibitor
viru
releas
neuraminidas
inhibitor
influenza
viru
bud
host
cell
viral
hemagglutinin
bind
receptor
cell
surfac
contain
nacetylneuramin
sialic
acid
residu
releas
virion
accomplish
action
neuraminidas
viral
surfac
cleav
termin
cellular
sialic
acid
residu
free
virion
spread
adjac
uninfect
cell
neuraminidas
inhibitor
oseltamivir
zanamivir
sialic
acid
analogu
bind
catalyt
site
neuraminidas
therebi
inhibit
viral
releas
spread
activ
domain
neuraminidas
highli
conserv
order
maintain
enzymat
function
howev
escap
mutant
emerg
monotherapi
patient
prolong
viru
shed
often
children
immunosuppress
individu
influenza
viru
strain
carri
resist
mutat
class
drug
circul
success
surprisingli
influenza
drug
limit
efficaci
clinic
applic
administ
within
h
onset
symptom
drug
reduc
durat
symptom
day
reduc
time
return
normal
activ
day
also
greater
research
invest
antivir
drug
hiv
viru
larg
number
infect
person
persist
natur
infect
fatal
rate
among
untreat
patient
creat
ethic
imper
offer
lucr
market
effect
therapi
gunthard
et
al
result
panopli
fdaapprov
product
tabl
action
drug
describ
forego
section
antivir
compound
abil
effect
treat
inevit
fatal
infect
one
great
triumph
scientif
medicin
guesstim
subject
age
recent
infect
hiv
optim
haart
highli
activ
antiretrovir
therapi
life
expect
year
contrast
year
absent
treatment
howev
present
regimen
control
hiv
replic
provid
cure
sinc
fail
erad
latent
hiv
genom
see
chapter
hivaid
hiv
drug
resist
loss
suscept
isol
subject
treat
first
antiretrovir
monotherapi
azt
associ
cumul
acquisit
mutat
target
gene
nrti
revers
transcriptas
explain
combin
three
differ
drug
need
figur
proteas
integras
inhibitor
usual
includ
combin
two
nrti
antiretrovir
regimen
initi
therapi
develop
fix
dose
combin
three
drug
singl
capsul
import
practic
advanc
enhanc
patient
complianc
becom
standard
regimen
present
million
peopl
receiv
singl
pill
daili
treat
hiv
tabl
hiv
prevent
anoth
import
applic
antiretrovir
treatment
preexposur
prophylaxi
prep
sever
trial
prep
appear
offer
potenti
power
adjunct
treatment
infect
patient
particularli
high
exposur
context
cohen
persist
hiv
genom
hivinfect
patient
initi
potent
combin
therapi
titer
viral
rna
plasma
drop
biphas
manner
see
figur
chapter
hivaid
earli
rapid
declin
last
week
slower
declin
last
sever
week
plateau
often
limit
detect
howev
treatment
stop
viremia
inevit
reappear
usual
week
indic
viral
erad
achiev
even
continu
lowlevel
hiv
replic
complet
suppress
persist
hiv
form
latent
provir
genom
rest
cell
preclud
erad
present
regimen
substanti
investig
effort
initi
identifi
approach
erad
latent
reservoir
would
requir
activ
latent
hiv
genom
kill
infect
cell
cohen
howev
best
longterm
initi
hcv
import
caus
human
diseas
sinc
estim
million
persist
infect
human
worldwid
mani
develop
chronic
hepat
liver
failur
hepatocellular
cancer
hcv
hepaciviru
positivestrand
rna
viru
flaviviru
famili
hcv
present
difficult
experiment
challeng
limit
cell
cultur
system
recent
improv
anim
model
chimpanze
natur
histori
hcv
cloud
insidi
asymptomat
natur
infect
patient
elimin
viru
within
month
infect
persist
infect
patient
experi
littl
chemic
clinic
evid
diseas
chronic
hepat
progress
endstag
cirrhosi
hepatocellular
cancer
period
year
data
indic
mani
patient
delic
balanc
hcv
host
defens
support
notion
antivir
therapi
could
lead
viral
clearanc
prior
treatment
hcv
focus
combin
ribavirin
pegyl
polyethylen
glycolconjug
interferon
produc
virolog
respons
sustain
mani
month
end
cours
treatment
substanti
number
cure
patient
infect
genotyp
hcv
howev
treatment
strategi
caus
seriou
toxic
side
effect
associ
longterm
administr
interferon
recent
discoveri
develop
drug
hcv
produc
revolut
therapi
de
clercq
rice
saeed
compound
call
directact
agent
daa
differenti
interferon
interferonfre
regimen
drug
target
hcv
polymeras
proteas
protein
result
viral
clearanc
without
relaps
effect
cure
treat
petta
craxi
recent
success
energ
develop
antivir
drug
mention
cours
hbv
infect
variabl
high
proport
patient
spontan
clear
viru
see
chapter
pattern
infect
persist
hbv
infect
divid
sever
categori
patient
lower
viru
titer
hbv
dna
copi
per
ml
serum
normal
liver
function
test
serum
alanin
aminotransferas
usual
treat
sinc
rel
low
risk
endstag
liver
diseas
cirrhosi
hepatocellular
carcinoma
treatment
ifn
either
nucleosid
nucleotid
revers
transcriptas
inhibitor
use
patient
sever
diseas
administ
parenter
month
year
induc
therapeut
respons
onethird
patient
howev
present
regimen
clear
viru
replic
resum
interrupt
drug
therapi
view
toxic
effect
prolong
interferon
treatment
low
respons
rate
present
therapi
need
improv
treatment
develop
potent
nucleosid
entecavir
nucleotid
tenofovir
hbv
polymeras
inhibitor
provid
toler
effect
longterm
treatment
major
obstacl
cure
hbv
exist
infect
hepatocyt
coval
close
circular
ccc
dna
maintain
viral
genom
nuclear
episom
one
approach
use
system
introduc
dna
nucleas
specif
cccdna
kennedi
et
al
dong
et
al
ahm
et
al
although
deliveri
system
vivo
challeng
number
drug
direct
hbv
enzym
use
develop
suppress
hbv
replic
reduc
level
cccdna
episom
shi
et
al
tavi
et
al
final
newli
develop
system
screen
antihbv
compound
suresh
et
al
ishida
et
al
estim
million
hbv
infect
worldwid
provid
major
incent
research
develop
current
invest
develop
hbv
drug
hold
promis
introduct
cur
regimen
sever
human
herpesvirus
caus
consider
morbid
rare
mortal
includ
herp
simplex
viru
hsv
cold
sore
genit
lesion
varicella
zoster
viru
vzv
chicken
pox
herp
zoster
cytomegaloviru
cmv
retin
complic
immunosuppress
subject
herpesviru
infect
offer
special
challeng
treatment
caus
persist
lifelong
latent
infect
intermitt
activ
activ
replic
accompani
diseas
latent
phase
viral
dna
maintain
nucleu
make
unlik
effect
therapi
erad
viru
therefor
treatment
direct
symptomat
phase
infect
herpesvirus
larg
dna
virus
encod
dna
polymeras
requir
transcript
genom
acyclovir
first
highli
effect
compound
treatment
hsv
vzv
nucleosid
analogu
dna
chain
termin
acyclovir
undergo
vivo
activ
addit
three
phosphat
side
chain
first
phosphat
ad
virusencod
thymidin
kinas
drug
convert
activ
triphosph
hsvand
vzvinfect
cell
second
third
phosphat
ad
cellular
kinas
acyclovir
triphosph
incorpor
nascent
dna
chain
butabs
riboseth
dna
polymeras
add
nucleotid
chain
termin
dual
viral
target
thymidin
kinas
dna
polymeras
acyclovir
confer
great
specif
henc
safeti
class
drug
sever
close
relat
compound
improv
clinic
activ
also
develop
lipidconjug
nucleotid
brincidofovir
dna
polymeras
inhibitor
activ
hsv
vzv
cmv
number
compound
direct
viral
polymeras
viral
protein
test
potenti
antiherpesviru
agent
among
nonnucleosid
compound
helicaseprimas
inhibitor
target
aspect
viral
dna
synthesi
absent
exogen
therapi
host
virusspecif
immun
respons
play
import
role
control
activ
phase
herpesviru
infect
repres
import
complementari
arm
therapi
fact
reimmun
vzvimmun
subject
reduc
incid
herp
zoster
elderli
ebola
zoonot
filoviru
caus
multipl
small
outbreak
africa
sinc
one
larg
pandem
west
africa
began
final
wane
may
see
chapter
emerg
viral
diseas
viewpoint
treatment
prevent
orphan
neglect
diseas
respons
ongo
pandem
crash
program
develop
ebola
treatment
initi
compound
earli
clinic
trial
tabl
recent
experiment
data
shown
cocktail
neutral
monoclon
antibodi
zmapp
ebola
viru
dramat
therapeut
effect
nonhuman
primat
model
close
simul
ebola
diseas
human
qui
et
al
murin
et
al
monkey
challeng
lethal
dose
ebola
viru
kill
anim
day
antibodi
treatment
initi
day
infect
andamazinglyit
protect
anim
report
recov
normal
health
crash
program
scale
product
antibodi
initi
knownat
writingwhen
avail
use
human
zmapp
similar
antibodi
cocktail
promis
therapi
appear
efficaci
intervent
far
develop
wide
varieti
compound
differ
mode
action
investig
potenti
drug
treat
ebola
one
propos
strategi
develop
algorithm
screen
fdaapprov
drug
antiebola
activ
ekin
coffe
vejlkov
et
al
litterman
et
al
field
move
rapidli
data
tabl
outdat
time
public
import
advanc
treatment
ebola
infect
rapid
pointofcar
diagnost
test
kit
reli
electr
power
refriger
complex
equip
highli
train
technician
test
approv
world
health
organ
first
antigen
rapid
test
ebola
abil
determin
whether
patient
present
fever
unknown
origin
ebolaendem
area
need
antiebola
treatment
critic
adjunct
effect
therapeut
intervent
also
relev
note
sever
promis
ebola
vaccin
candid
human
trial
west
africa
see
chapter
viral
vaccin
approv
human
use
also
serv
critic
tool
control
ebola
outbreak
rampl
et
al
agnandji
et
al
lipsitch
et
al
marzi
et
al
practic
note
one
ironi
develop
ebola
treatment
pandem
waningmay
new
compound
readi
clinic
trial
kuehn
fleck
kupferschmidt
hope
possibl
test
safeti
intervent
appear
promis
could
use
compassion
basi
next
outbreak
occur
excit
futur
develop
new
antivir
drug
energ
recent
success
hcv
consider
guid
field
near
futur
scientif
public
health
issu
play
scientif
arena
set
forth
figur
number
pathway
drug
develop
directact
antivir
compound
virusspecif
directact
compound
somewhat
gener
cellular
target
virusspecif
broad
cellular
target
pathogenesi
differ
infect
import
role
select
efficaci
put
drug
great
potenti
drug
treat
persist
infect
seriou
longterm
consequ
drug
may
less
practic
acut
infect
resolv
virusspecif
diagnosi
made
molecular
natur
virushost
infect
import
sinc
determin
whether
drug
control
infect
also
lead
perman
cure
comparison
hiv
control
cure
hcv
control
cure
illustr
point
guid
search
effect
antivir
compound
recent
success
hcv
hiv
suggest
directact
antivir
molecul
still
remain
gold
standard
inform
mani
initi
one
achil
heel
compound
viral
escap
extens
experi
hiv
shown
use
tripl
combin
overcom
problem
recent
experi
hcv
provid
sever
lesson
understand
viru
replic
cycl
molecular
level
pave
way
identif
candid
compound
insight
use
construct
highthroughput
screen
assay
strategi
lead
product
clinic
effect
safe
scheel
rice
kim
et
al
rice
saeed
burgeon
field
system
biolog
offer
signific
new
strategi
identifi
antivir
compound
particularli
intertwin
field
cellular
target
drug
repurpos
tabl
drug
target
host
function
alway
carri
risk
unwant
side
effect
particularli
longterm
drug
treatment
howev
toxic
may
less
issu
drug
use
treat
acut
infect
ebola
hemorrhag
fever
util
drug
direct
molecul
hiv
treatment
demonstr
viabl
strategi
era
person
precis
medicin
infanc
see
gari
gilliland
commentari
chapter
lie
ahead
fact
person
treatment
regimen
alreadi
standard
practic
certain
persist
viral
infect
hepat
b
c
lok
futur
trial
candid
drug
includ
genet
data
particip
determin
drug
efficaci
toxic
local
subpopul
insel
et
al
ramamoothri
et
al
johannessen
et
al
may
rescu
certain
candid
compound
use
preselect
patient
given
consider
viral
diseas
may
target
drug
develop
near
futur
list
persist
infect
would
includ
hbv
hpv
herpesvirus
instanc
larg
global
popul
infect
person
would
benefit
cure
addit
cure
control
larg
number
viru
carrier
impact
preval
popul
among
acut
infect
carri
high
mortal
would
candid
particularli
virus
epidem
potenti
ebola
hemorrhag
fever
tabl
dengu
influenza
type
virus
also
high
list
experi
exist
influenza
antivir
compound
indic
viral
escap
common
mandat
need
multipl
drug
therapi
use
inform
pharmaceut
compani
research
tool
enabl
develop
select
compound
signific
antivir
activ
howev
drug
develop
becom
daunt
challeng
due
scientif
hurdl
financi
requir
vivo
bioavail
pharmacodynam
potenti
toxic
addit
major
obstacl
must
overcom
develop
safe
effect
antivir
chemotherapeut
develop
new
drug
discoveri
licensur
often
take
long
year
cost
billion
dollar
repurpos
drug
alreadi
approv
human
use
could
help
address
obstacl
clearli
excit
futur
antivir
drug
develop
de
clercq
field
demonstr
practic
yield
research
basic
virolog
viral
pathogenesi
viral
epidemiolog
howev
support
orphan
drug
particularli
great
neglect
diseas
remain
major
ethic
strateg
challeng
highincom
countri
govern
privat
sector
alik
karan
pogg
date
fail
implement
effect
strategi
develop
distribut
therapeut
neglect
infecti
diseas
continu
plagu
lowincom
countri
